Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R Bogner, David Baker, Marie-Aude Khuong-Josses, David Parks, Konstantinos Angelis, Lesley P Kahl, Elizabeth A Blair, Kimberly Adkison, Mark Underwood, Jessica E Matthews, Brian Wynne, Kati Vandermeulen, Martin Gartland, Kimberly Smith
BACKGROUND: Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four-drug antiretroviral regimen for maintenance of virological suppression in people with HIV-1. Here, we present efficacy and safety data from the 100-week analysis of the trials. METHODS: SWORD-1 and SWORD-2 are identically designed, randomised, open-label phase 3 studies at 65 centres in 13 countries and 60 centres in 11 countries, respectively...
September 2019: Lancet HIV